Poseida Therapeutics Inc
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies an… Read more
Market Cap & Net Worth: Poseida Therapeutics Inc (PSTX)
Poseida Therapeutics Inc (NASDAQ:PSTX) has a market capitalization of $925.93 Million ($925.93 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9295 globally and #4499 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Poseida Therapeutics Inc's stock price $9.50 by its total outstanding shares 97466704 (97.47 Million).
Poseida Therapeutics Inc Market Cap History: 2020 to 2025
Poseida Therapeutics Inc's market capitalization history from 2020 to 2025. Data shows change from $1.07 Billion to $925.93 Million (-10.12% CAGR).
Poseida Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Poseida Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.06x
Poseida Therapeutics Inc's market cap is 5.06 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $663.75 Million | $31.24K | $4.40 Million | 21248.10x | 150.72x |
| 2022 | $516.57 Million | $130.36 Million | -$64.00 Million | 3.96x | N/A |
| 2023 | $327.49 Million | $64.70 Million | -$123.43 Million | 5.06x | N/A |
Competitor Companies of PSTX by Market Capitalization
Companies near Poseida Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Poseida Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Poseida Therapeutics Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Poseida Therapeutics Inc's market cap moved from $1.07 Billion to $ 925.93 Million, with a yearly change of -10.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $925.93 Million | -1.04% |
| 2024 | $935.68 Million | +185.71% |
| 2023 | $327.49 Million | -36.60% |
| 2022 | $516.57 Million | -22.17% |
| 2021 | $663.75 Million | -37.92% |
| 2020 | $1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Jan 6th, 2026 the market cap of Poseida Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $925.93 Million USD |
| MoneyControl | $925.93 Million USD |
| MarketWatch | $925.93 Million USD |
| marketcap.company | $925.93 Million USD |
| Reuters | $925.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.